In 2025, NNE delivered on its strategy by executing the largest pharma project portfolio in the company’s history, including some of the most complex pharma projects ever undertaken. The scale and scope of this execution are reflected in the financial results, with sales increasing by 16% to more than DKK 4,500 million and an operating profit margin of 12%.
